Goodwin advised RA Pharmaceuticals on the deal Ra Pharmaceuticals, Inc. (NASDAQ: RARX) executed the pricing of an underwritten public offering of 8,400,000 shares of its common…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
